HOME | COUNTRIES | CITIES | COMPANIES | SPORTS | CARS
news videos images websites
 

Regeneron Pharmaceuticals NEWS

NFE/5.0en-USnews-webmaster@google.com2019 Google Inc.Wed, 13 Feb 2019 20:04:15 GMTGoogle News
Regeneron: Cheap Enough To Look Past The Eylea Valley  Seeking Alpha

REGN's major 2017 product intro, Dupixent, is seeing booming sales. Dupixent probably has several new indications coming and is in the early stages of its ...

Seeking Alpha
Regeneron Pharmaceuticals beats by $1.23, beats on revenue  Seeking Alpha

Regeneron Pharmaceuticals (REGN): Q4 Non-GAAP EPS of $6.84 beats by $1.23; GAAP EPS of $7.15 beats by $1.73. Revenue of $1.93B (+22.2% Y/Y) beats ...

Seeking Alpha
Centre Asset Management Decreased Holding in Regeneron Pharmaceuticals (REGN) as Market Valuation Declined; As Compass Minerals Int (CMP) Stock Declined, Shareholder Beacon Financial Group Trimmed Stake  The Hi New Ulm

Centre Asset Management Llc decreased its stake in Regeneron Pharmaceuticals (REGN) by 3.76% based on its latest 2018Q3 regulatory filing with the SEC.

The Hi New Ulm
Regeneron Likely To Outperform In 2019  Seeking Alpha

Regeneron is a biotech company with revenue earning drugs and a decent pipeline. Regeneron has performed poorly for years but is also very volatile, and ...

Seeking Alpha
Regeneron Pharmaceuticals Inc. (REGN) Dips 3.36% for January 22  Equities.com

Regeneron Pharmaceuticals Inc. is a Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular ...

Equities.com
Regeneron Pharmaceuticals: An Elliott Wave Forecast Worthy of the "Super Bowl of Science"  Elliott Wave International

See the before and after: Trader's Classroom editor Jeffrey Kennedy recently forecast a big move, with clear Elliott Wave labels and a large "up" arrow.

Elliott Wave International
Regeneron will spend up to $490 million on manufacturing, labs this year  Albany Business Review

Regeneron spent $383.1 million on capital expenditures last year, an increase of $110 million from 2017.

Albany Business Review
Why I Like Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)  Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Regeneron Pharmaceuticals, Inc.

Simply Wall St
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Average Broker Recommendation Watch on These Shares  Hawthorn Caller

Wall Street analysts have the ability to provide stock ratings for companies that they track. Based on analysts used by Zacks Research, the present average.

Hawthorn Caller
Now Offering Discount Or Premium? – Chesapeake Energy Corporation (CHK), Regeneron Pharmaceuticals, Inc. (REGN)  Post Analyst

Chesapeake Energy Corporation (NYSE:CHK), with a trailing 12-month price-to-sales ratio of 0.23, is now among the bigger bargains in its industry. The broad ...

Post Analyst
Regeneron to Report Fourth Quarter and Full Year 2018 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2019  PRNewswire

TARRYTOWN, N.Y., Jan. 18, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and ...

PRNewswire
Comparing of Regeneron Pharmaceuticals Inc. (REGN) and ImmunoGen Inc. (NASDAQ:IMGN)  The FinHeadLines

As Biotechnology companies, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and ImmunoGen Inc. (NASDAQ:IMGN) are our subject to compare. And more ...

The FinHeadLines
Regeneron Pharmaceuticals Inc. (REGN)'s Financial Results Comparing With Audentes Therapeutics Inc. (NASDAQ:BOLD)  The Moveefy

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Audentes Therapeutics Inc. (NASDAQ:BOLD) are two firms in the Biotechnology that compete against ...

The Moveefy
Regeneron Pharmaceuticals, Inc. (REGN) Looking for a Catalyst the Book to Market Ratio Hits 0.173694  Richland Standard

Regeneron Pharmaceuticals, Inc. (REGN) is yielding a market ratio of 0.173694. The book to market ratio is a relative valuation ratio which divides.

Richland Standard
Regeneron Pharmaceuticals Inc. (REGN) and Autolus Therapeutics plc (NASDAQ:AUTL) Comparison side by side  Lives Advice

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Autolus Therapeutics plc (NASDAQ:AUTL), are influenced by compare since they are both players in the ...

Lives Advice
Royal London Asset Management Ltd. Boosts Stake in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

Royal London Asset Management Ltd. grew its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 5.8% during the 4th quarter, according ...

Fairfield Current
Reviewing Regeneron Pharmaceuticals Inc. (REGN)'s and Portola Pharmaceuticals Inc. (NASDAQ:PTLA)'s results  Port Courier

Both Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Portola Pharmaceuticals Inc. (NASDAQ:PTLA) are Biotechnology companies, competing one ...

Port Courier
As Regeneron Pharmaceuticals (REGN) Stock Value Declined, Temasek Holdings Private LTD Has Lowered Stake; Canal Insurance Company Has Boosted Bank Of America Ord (BAC) Stake by $1.02 Million; Stock Value Declined  The Yomi Blog

Temasek Holdings Private Ltd decreased its stake in Regeneron Pharmaceuticals (REGN) by 33.72% based on its latest 2018Q3 regulatory filing with the SEC.

The Yomi Blog
Regeneron Pharmaceuticals (REGN) Raised to Buy at Guggenheim  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by equities research analysts at Guggenheim from a “neutral” rating to a “buy” rating in a research ...

Fairfield Current
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio  Nasdaq

For Immediate Release Chicago, IL - January 24, 2019 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks.

Nasdaq
Minerva Neurosciences Inc. (NERV) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Contrasting side by side  The Moveefy

Since Minerva Neurosciences Inc. (NASDAQ:NERV) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are part of the Biotechnology industry, they are ...

The Moveefy
Getting Defensive In Emerging Markets: Regeneron Pharmaceuticals, Inc. (REGN)  MONReport

Wall Street analysts will be watching closely when Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reports its quarterly earnings next, which is scheduled for ...

MONReport
Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%  Zacks.com

Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of ...

Zacks.com
Associate Director, I.P. (Trademarks, Copyright, and Trade Secrets) – Large Corporation – Tarrytown, N.Y.  Patently-O

Regeneron Pharmaceuticals Inc. is seeking an intellectual property attorney at the Associate Director level to help in the development, protection, and ...

Patently-O
Regeneron in line for $70 million grant  Times Union

ALBANY — Regeneron Pharmaceuticals is in line for a $70 million grant from the state that will help the company significantly expand its operations in East ...

Times Union
CTI BioPharma Corp. (CTIC) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Comparing side by side  The Yomi Blog

CTI BioPharma Corp. (NASDAQ:CTIC) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are two firms in the Biotechnology that compete against each ...

The Yomi Blog
Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN): A Look Into the Volatility & Valuation  Olla Journal

The 12 month volatility of Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) is 34.505100. This is calculated by taking weekly log normal returns and.

Olla Journal
Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) Enterpise Value of 43198290 Puts Quant in Focus  Steele Herald

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) presently has an EV or Enterprise Value of 43198290. The EV helps show how the market assigns value ...

Steele Herald
Wasatch Advisors Increases Position in Ipg Photonics Corp. (IPGP); Regeneron Pharmaceuticals (REGN) Valuation Declined While Sustainable Growth Advisers LP Cut Stake  The Moveefy

Wasatch Advisors Inc increased its stake in Ipg Photonics Corp. (IPGP) by 260.76% based on its latest 2018Q3 regulatory filing with the SEC. Wasatch Advisors ...

The Moveefy
Regeneron Pharmaceuticals Inc (REGN) Position Trimmed by Avestar Capital LLC  Fairfield Current

Avestar Capital LLC reduced its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 15.5% in the fourth quarter, according to the company in its ...

Fairfield Current
Are These Stocks Fairly Valued? Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), RELX PLC (LSE:REL)  Martin Business Telegraph

In order to determine if a company is fairly valued, we can look at a number of different ratios and metrics. First off we'll take a look at the Price to.

Martin Business Telegraph
Regeneron Pharmaceuticals, Inc. (REGN): Quant Investors Taking Note of the 0.315422 Gross Profitability Score  Richland Standard

Investors interested in quality ratios for Regeneron Pharmaceuticals, Inc. (REGN) should take a good look at the Gross Profitability of the stock. Robert.

Richland Standard
As Regeneron Pharmaceuticals (REGN) Stock Declined, Shareholder Sumitomo Mitsui Trust Holdings Boosted Its Stake; Argent Capital Management Has Trimmed Holding in Las Vegas Sands Corp. (LVS) as Valuation Declined  Thе Mоnіtоr

Sumitomo Mitsui Trust Holdings Inc increased its stake in Regeneron Pharmaceuticals (REGN) by 2.45% based on its latest 2018Q3 regulatory filing with the ...

Thе Mоnіtоr
Regeneron Pharmaceuticals Inc (REGN) Holdings Reduced by New York State Teachers Retirement System  PressOracle

New York State Teachers Retirement System decreased its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 3.7% in the fourth quarter, ...

PressOracle
Focusing The Lens on These Shares: Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), The Kraft Heinz Company (NasdaqGS:KHC)  Richland Standard

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) currently has a current ratio of 4.47. The current ratio, which is also known as the working capital ratio, is a.

Richland Standard
Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?  Zacks.com

Strong Eylea and Dupixent sales are likely to propel better-than-expected results for Regeneron (REGN) when it reports fourth-quarter results.

Zacks.com
Regeneron profits double ahead of $800 million expansion  Albany Business Review

The drug developer's growth fueled last year's decision to move forward with an $800 million manufacturing expansion in East Greenbush, New York, a few ...

Albany Business Review
Shares in Focus: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)  Preston Business Review

Taking a quick look at the historical performance of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares, we have noted that the stock price for the.

Preston Business Review
Understanding Analyst Rating: Regeneron Pharmaceuticals (REGN)  Voice Of Analysts

Regeneron Pharmaceuticals (REGN) moved -1.02% to 421.04 on Tuesday. Regeneron Pharmaceuticals received interesting focus from Active Investors and it ...

Voice Of Analysts
Microsoft (MSFT) Holder Community Financial Services Group Has Trimmed Holding; As Regeneron Pharmaceuticals (REGN) Valuation Declined, Truenorth Increased Position  The FinReviewer

Community Financial Services Group Llc decreased its stake in Microsoft Corp (MSFT) by 2.24% based on its latest 2018Q3 regulatory filing with the SEC.

The FinReviewer
Truenorth Has Increased Its Stake in Regeneron Pharmaceuticals (REGN) by $349,056 as Share Value Declined; Texas Pac Ld Tr (TPL) Stock Price Declined While Pacific Heights Asset Management Lowered by $12.93 Million Its Holding  The Hi New Ulm

Truenorth Inc increased its stake in Regeneron Pharmaceuticals (REGN) by 12.21% based on its latest 2018Q3 regulatory filing with the SEC. Truenorth Inc ...

The Hi New Ulm
Analyst Research and Ratings: Cameco Corporation (CCJ), Regeneron Pharmaceuticals, Inc. (REGN)  Analyst Journal

Cameco Corporation (NYSE:CCJ) tinted loss of -0.08% (-0.01 points) to US$12.4. The volume of 1.51 Million shares climbed down over an trading activity of ...

Analyst Journal
Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) Has Posted Sales Growth of 0.14280 YoY  Winslow Record

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) have seen a year over year change of sales growth of 0.14280. The 43959338 market value company ...

Winslow Record
Meiji Yasuda Life Insurance Company Holding In Regeneron Pharmaceuticals (REGN) Was Has Upped; Fidelity National Information Services (FIS) Shareholder Capital Fund Management Sa Has Cut Holding as Stock Value Declined  The FinHeadLines

Meiji Yasuda Life Insurance Company increased its stake in Regeneron Pharmaceuticals (REGN) by 46.66% based on its latest 2018Q3 regulatory filing with ...

The FinHeadLines
Atopic Dermatitis Treatment Market | Global Research Insight 2019-2025 (Sanofi, Regeneron Pharmaceuticals, Astellas Pharma)  Market News Press Release

Global Atopic Dermatitis Treatment market report 2018 provides information about market dynamics, leading manufacturers, segmentation, types, applications, ...

Market News Press Release
Analyst Opinion Summary: Tenneco Inc. (TEN), Regeneron Pharmaceuticals, Inc. (REGN)  Analyst Journal

Tenneco Inc. (NYSE:TEN) tinted gains of +2.54% (+0.86 points) to US$34.72. The volume of 0.47 Million shares climbed down over an trading activity of 695.82 ...

Analyst Journal
3 Healthcare Stocks Hitting 52-Week Highs: Are They Buys?  The Motley Fool

Can the sizzling momentum continue for these high-flying healthcare stocks?

The Motley Fool
Chappaqua, Ossining and Byram Hills students named finalists in 2019 Regeneron contest  The Journal News | LoHud.com

Four students from Chappaqua, Ossining and Byram Hills were named finalists in the highly competitive Regeneron Science Talent Search competition.

The Journal News | LoHud.com
Analyst Research Roundup: Regeneron Pharmaceuticals, Inc. (REGN), Aerojet Rocketdyne Holdings, Inc. (AJRD)  Analyst Journal

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) tinted gains of +1.67% (+6.72 points) to US$407.93. The volume of 0.65 Million shares climbed down over ...

Analyst Journal
Regeneron Pharmaceuticals (REGN) Stake Has Lifted by Bbva Compass Bancshares Inc; Jrm Investment Counsel Has Raised Stake in Blackstone Mtg Tr (BXMT) by $1.54 Million as Stock Price Rose  The Hi New Ulm

Bbva Compass Bancshares Inc increased its stake in Regeneron Pharmaceuticals (REGN) by 7.38% based on its latest 2018Q3 regulatory filing with the SEC.

The Hi New Ulm
3 of the Top Big Pharma Stocks to Buy Now  Investorplace.com

Big pharma stocks are getting good coverage from JPMorgan's healthcare event. Here are three undervalued pharmaceutical stocks to buy now.

Investorplace.com
Retinal Biologics Market is Growing Worldwide with Leading key players Regeneron Pharmaceuticals, AbbVie, Johnson & Johnson Services  GloballUp

HTF MI recently Announced Global Retinal Biologics study with 100+ market data Tables and Figures spread through Pages and easy to understand detailed ...

GloballUp
Analysts’ Recent Ratings Changes for Regeneron Pharmaceuticals (REGN)  Baseball Daily News

Several brokerages have updated their recommendations and price targets on shares of Regeneron Pharmaceuticals (NASDAQ: REGN) in the last few weeks: ...

Baseball Daily News
What Analyst Recommends Average Price Target? Regeneron Pharmaceuticals (REGN)  Voice Of Analysts

Regeneron Pharmaceuticals (REGN) stock price exposed a move of 8.37% so far this year and uncovered flow of 8.94% in recent year. The stock managed ...

Voice Of Analysts
Global Atopic Dermatitis Treatment Market 2018 Latest Innovations – Sanofi, Regeneron Pharmaceuticals, Astellas Pharma, Anacor Pharmaceuticals  Buffalo Morning Star

The report by Fior Markets namely, Global Atopic Dermatitis Treatment Market Research Report 2018 focuses on key drivers and restraints for the key players.

Buffalo Morning Star
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Stake Boosted by Boston Common Asset Management LLC  PressOracle

Boston Common Asset Management LLC grew its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 27.3% during the fourth quarter, ...

PressOracle
Diabetic Macular Edema Market: Industry Statistics Report 2025; Alimera Sciences Inc., Regeneron Pharmaceuticals Inc., Pfizer Inc.  Eagle Chronicle

The Report Global Diabetic Macular Edema Market published by Crystal Market Research discusses the present as well as the predicted growing demand with ...

Eagle Chronicle
Regeneron Pharmaceuticals Inc (REGN) Expected to Announce Earnings of $5.63 Per Share  Baseball Daily News

Wall Street analysts forecast that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post earnings per share of $5.63 for the current quarter, Zacks reports.

Baseball Daily News
Under Armour, Inc. (UAA) registers a price change of 2.14% while Regeneron Pharmaceuticals, Inc. (REGN) finishes with a flow of 3.17%  Stocks Gallery

As close of Thursday trade, Under Armour, Inc. (UAA) is standing at value of $20.03 with the rising stream of 2.14%. Active Investors have to observe some key ...

Stocks Gallery
Global Retinal Biologics Market 2019 - Regeneron Pharmaceuticals, Inc, AbbVie Inc, Johnson Johnson Services, Inc, Amgen Inc  ApexNewsRoom

In 2018, the global Retinal Biologics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during ...

ApexNewsRoom
Regeneron Pharmaceuticals, Inc. (REGN) stock price of $429.27 to 2.23% while 50-day Moving Average change of 13.34%  Top desert News

Regeneron Pharmaceuticals, Inc. (REGN) stock go up so far this year; showing a rise of 14.93% and added with positive flow of 5.23% during recent week.

Top desert News
Review the Facts about stock: Regeneron Pharmaceuticals (REGN)  Connecting Investor

Regeneron Pharmaceuticals (REGN) Stock's Price Fluctuations & Volatility: The stock price registered volatility 3.09% in past week and volatility was at 2.58% ...

Connecting Investor
Federated Investors Inc. PA Sells 221 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Baseball Daily News

Federated Investors Inc. PA cut its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 8.8% in the 3rd quarter, according to its most recent ...

Baseball Daily News
Long-Term Outlook For Regeneron Pharmaceuticals  Seeking Alpha

REGN is retracing its levels from January 2018 after hitting lows in May and highs in September. Revenue continues to grow and REGN has a strong history of ...

Seeking Alpha
Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals  The Motley Fool

Ascending and descending? That might be how some investors view Vertex Pharmaceuticals (NASDAQ:VRTX) and Regeneron Pharmaceuticals ...

The Motley Fool
Biotech Bio Series #4: Regeneron Is Not Done  Seeking Alpha

Regeneron is down around 10% over the past year, despite continuing to make pipeline advances. Eylea, currently its main revenue driver, continues to deliver ...

Seeking Alpha
Regeneron Pharmaceuticals beats by $0.73, beats on revenue  Seeking Alpha

Regeneron Pharmaceuticals (REGN): Q3 Non-GAAP EPS of $5.87 beats by $0.73; GAAP EPS of $5.17 beats by $0.69. Revenue of $1.66B (+10.7% Y/Y) beats ...

Seeking Alpha
Will Regeneron Close At $400?  Seeking Alpha

Shares of Regeneron closed at my target price after reporting a solid second quarter. Company is suitable for long-term investors only. Does REGN's stock ...

Seeking Alpha
How Libtayo's Approval May Help Cure Regeneron's Remaining Ills  Seeking Alpha

Regeneron and its partner Sanofi received a gift from the FDA Friday with approval of their immuno-oncology drug Libtayo a month before its PDUFA date.

Seeking Alpha
Regeneron Pharmaceuticals Inc (REGN) Q3 2018 Earnings Conference Call Transcript  Motley Fool

REGN earnings call for the period ending September 30, 2018.

Motley Fool
Regeneron to receive up to $140 million from state toward $800 million expansion  Albany Business Review

The pharmaceuticals manufacturer plans to invest $800 million and hire 1500 people in East Greenbush to increase its production over the next seven years.

Albany Business Review
Regeneron: Regenerating As Usual  Seeking Alpha

Regeneron's stock has been volatile lately, but the shareholders got used to the stock movements in the last four years. At current levels, Regeneron's upside d.

Seeking Alpha
Regeneron Pharmaceuticals (REGN) Q2 2018 Results - Earnings Call Transcript  Seeking Alpha

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Q2 2018 Earnings CallAugust 02, 2018 8:30 am ETExecutivesManisha A. Narasimhan - Regeneron ...

Seeking Alpha
Regeneron Pharmaceuticals Tops Second-Quarter Sales, Earnings Views  Investor's Business Daily

Regeneron Pharmaceuticals on Thursday reported adjusted income of $5.45 per share on $1.61 billion in sales for the second quarter.

Investor's Business Daily
Regeneron's Latest CRL Is Just A Minor Inconvenience That Can Be Dealt With Quickly  Seeking Alpha

Regeneron Pharmaceuticals received CRL for supplemental NDA for Eylea as a pre-filled syringe. Regeneron expects that it can file its response to the FDA for ...

Seeking Alpha
Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies  Zacks.com

Eli Lilly and Company (LLY) and partner Incyte's Olumiant meets primary endpoint in two phase III studies evaluating it for moderate-to-severe atopic dermatitis.

Zacks.com
Is Regeneron Pharmaceuticals, Inc. a Buy?  The Motley Fool

Many biotech stocks have performed quite well over the last 12 months. But not Regeneron Pharmaceuticals (NASDAQ:REGN). For much of 2017, Regeneron ...

The Motley Fool
Regeneron Stock Is the Latest Biotech Bottle Rocket  Barron's

Guggenheim's Adnan Butt boosted his rating on the stock to Buy from Hold, with a $461 price target, citing valuation, and more confidence that the company can ...

Barron's
Regeneron's Price Implies Opportunity  Seeking Alpha

Regeneron is a stock that has seen a substantial and prolonged decline until recently, to the puzzlement of many. The company is a consistent leader with its Tr.

Seeking Alpha
Regeneron Reports Q3: Updating Its Growth Prospects  Seeking Alpha

REGN has been providing a lot of news on important products lately. It announced earnings Tuesday, which were solid, but Eylea growth has slowed.

Seeking Alpha
Regeneron Achieves An FDA First With Immunotherapy Cancer Product  Seeking Alpha

Regeneron and its partner Sanofi obtain FDA approval for Libtayo treating patients with metastatic cutaneous squamous cell carcinoma. The biotech made ...

Seeking Alpha
Trump's drug price crack down could squeeze Regeneron and Eylea profits  Albany Business Review

"Something has to change in how Medicare pays for physician-administered drugs," said U.S. Health and Human Services Secretary Alex Azar.

Albany Business Review
Regeneron Pharmaceuticals, Inc. Financials and News | 100 Best Workplaces for Millennials  Fortune

Employees say: "Regeneron is all about innovation. Whether it is in our scientific endeavors, employee recognition programs, or seasonal celebrations we are ...

Fortune
Regeneron will invest $800 million, expand workforce by 1,500  Albany Business Review

Regeneron Pharmaceuticals will invest $800 million and hire an additional 1,500 employees in East Greenbush, New York, as the drug maker increases ...

Albany Business Review
Does Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) CEO Salary Reflect Performance?  Simply Wall St

In 1988 Leonard Schleifer was appointed CEO of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). This analysis aims first to contrast CEO compensation ...

Simply Wall St
Regeneron: A Buy On Dupixent And Pipeline  Seeking Alpha

Regeneron (REGN) is priced nicely for buyers, given its profit growth and clinical pipeline of potential new drugs. Regeneron is a large cap ($38.8 billion) ...

Seeking Alpha
Regeneron: The Catalysts  Seeking Alpha

The objective of vision gains over convenience might meaningfully differentiate Eylea from both Lucentis and RTH258 and help it maintain market share in 2020.

Seeking Alpha
Why Is Regeneron Pharmaceuticals (REGN) Up 2.7% Since Its Last Earnings Report?  Zacks.com

Regeneron Pharmaceuticals (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks.com
Regeneron Pharmaceuticals Inc. v. Merus N.V.  SCOTUSblog

Issue: Whether a patent right can be fully extinguished based on misconduct committed by the patentee's counsel during federal district court litigation to enforce ...

SCOTUSblog
Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential  Zacks.com

Regeneron Pharmaceuticals (REGN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid ...

Zacks.com
Regeneron's Eylea generated over $4B in U.S. sales in 2018  Seeking Alpha

Regeneron Pharmaceuticals (REGN) announces preliminary U.S. sales of EYLEA (aflibercept) of $4.07B (+10%), based on Q4 sales of $1.07B. Key milestones ...

Seeking Alpha
Why Regeneron Has 30 Percent Upside  Seeking Alpha

Regeneron reported exceptionally strong earnings growth in the first quarter. Dupixent prescriptions strong. Coverage for expensive therapy a headwind for ...

Seeking Alpha
Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?  Zacks.com

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Regeneron ...

Zacks.com
Regeneron Pharmaceuticals is Now Oversold (REGN)  Nasdaq

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level ...

Nasdaq
The Bull Case for Regeneron Pharmaceuticals Inc Couldn’t Be More Clear  Yahoo Finance

After falling from $393 per share early this year to a recent low of $284 per share, analysts have begun pounding the table again for Regeneron Pharmaceuticals ...

Yahoo Finance
Dupixent: Top-Down And Bottom-Up Perspectives On The News  Seeking Alpha

The Regeneron/Sanofi anti-allergy drug Dupixent was reported Tuesday to have passed its latest Phase 3 pivotal trials with flying colors. The condition treated.

Seeking Alpha
Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron  Seeking Alpha

Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years.

Seeking Alpha
Regeneron Pharmaceuticals (REGN) Q1 2018 Results - Earnings Call Transcript  Seeking Alpha

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Q1 2018 Earnings CallMay 03, 2018 8:30 am ETExecutivesManisha A. Narasimhan - Regeneron ...

Seeking Alpha
 

Regeneron Pharmaceuticals Videos

Regeneron Pharmaceuticals CEO: Changing Medicine | Mad Money | CNBC
18:38:46
Regeneron Pharmaceuticals CEO: Changing Medicine | Mad Money | CNBC
Leonard S. Schleifer, MD, PHD, Founder, President & CEO, Regeneron Pharmaceuticals
14:48:43
Leonard S. Schleifer, MD, PHD, Founder, President & CEO, Regeneron Pharmaceuticals
Regeneron
21:07:37
Regeneron
Inside The Gene Factory | Forbes
20:41:52
Inside The Gene Factory | Forbes
Regeneron Pharmaceuticals CEO Talks Business
07:02:34
Regeneron Pharmaceuticals CEO Talks Business
The Next Big Thing in Biotech: Regeneron Pharmaceuticals
09:17:54
The Next Big Thing in Biotech: Regeneron Pharmaceuticals
Welcome to Regeneron
18:58:17
Welcome to Regeneron
Regeneron: The Path from Basic Research to Commercial Product
16:54:10
Regeneron: The Path from Basic Research to Commercial Product
Building A Biotech | Forbes
12:59:09
Building A Biotech | Forbes
Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer | Mad Money | CNBC
12:20:41
Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer | Mad Money | CNBC
 

Regeneron Pharmaceuticals Images

Regeneron Pharmaceuticals (REGN) presents at 35th Annual J ...
Regeneron Pharmaceuticals (REGN) presents at 35th Annual J ...
Regeneron Pharmaceuticals (REGN) Stock Price, Financials ...
Regeneron Pharmaceuticals (REGN) Stock Price, Financials ...
Pitney Bowes signs new lease at Rensselaer Technology Park ...
Pitney Bowes signs new lease at Rensselaer Technology Park ...
Regeneron Tenant Improvements Project | The Pike Company
Regeneron Tenant Improvements Project | The Pike Company
Regeneron and Sanofi Announce FDA Approval of DUPIXENT ...
Regeneron and Sanofi Announce FDA Approval of DUPIXENT ...
Amneal Pharmaceuticals – JM2 Architecture
Amneal Pharmaceuticals – JM2 Architecture
EMERGING APPROACHES TO COMBINATION THERAPIES IN AMD & DME ...
EMERGING APPROACHES TO COMBINATION THERAPIES IN AMD & DME ...
Eylea (Aflibercept) for Treatment for Wet AMD - Drug ...
Eylea (Aflibercept) for Treatment for Wet AMD - Drug ...
FDA Approves New Cholesterol Drug Praluent
FDA Approves New Cholesterol Drug Praluent
Sze Yen ‘John’ Kerk and Alana Mendelsohn are the winners ...
Sze Yen ‘John’ Kerk and Alana Mendelsohn are the winners ...
 

Regeneron Pharmaceuticals WebSites

Regeneron (NASDAQ: REGN) is a leading biotechnology company using the power of science to bring new medicines to patients in need.
Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Eastview, near Tarrytown, New York.The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical ...
Patient advocacy groups campaign to raise awareness of diseases, to fund research and to promote policies favorable to their causes on Capitol Hill and at the Food and Drug Administration. But do ...
Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases. Read on
Regeneron’s organized chaos is balanced by an entrepreneurial spirit and a comprehensive support system that encourages employees to disrupt the status quo.
Stock quote for Regeneron Pharmaceuticals, Inc. Common Stock Common Stock (REGN) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq.
Find real-time REGN - Regeneron Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business.
Real-time trade and investing ideas on Regeneron Pharmaceuticals, Inc. REGN from the largest community of traders and investors.
Regeneron Pharmaceuticals, Inc. (REGN) News – Find the latest company news headlines for Regeneron Pharmaceuticals, Inc. and all the companies you research at NASDAQ.com